Abstract
The catechol-O-methyltransferase (COMT) is a major degrading enzyme in the metabolic pathways of catecholaminergic neurotransmitters such as dopamine and norepinephrine. This study investigated whether the functionally relevant Val108/158Met gene variant is associated with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized clinical trial with both drugs. In patients treated with mirtazapine, but not paroxetine, allelic variations in the COMT gene were associated with differential response. COMTVAL/VAL and COMTVAL/MET genotype carriers showed a better response than COMTMET/MET-bearing patients in the mirtazapine group. Moreover, carriers of the COMTVAL/VAL or COMTVAL/MET genotype had significantly greater HAMD-17 (Hamilton Rating Scale for Depression 17 item version) score reductions than COMTMET/MET homozygotes from week 2 to 6, respectively, in the mirtazapine group. Time course of response and antidepressant efficacy of mirtazapine, but not paroxetine, seem to be influenced in a clinically relevant manner by this allelic variation within the COMT gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M . Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508–511.
Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E . Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105–107.
Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215–219.
Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–590.
Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E . Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001; 11: 375–380.
Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E . Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586–592.
Muller DJ, Schulze TG, Macciardi F, Ohlraun S, Gross MM, Scherk H et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry 2002; 35: 157–158.
Fawcett J, Barkin RL . Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267–285.
Kent JM . SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911–918.
Mannisto PT, Kaakkola S . Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51: 593–628.
Lee MS, Lyoo CH, Ulmanen I, Syvanen AC, Rinne JO . Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001; 298: 131–134.
Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR . The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000; 23: 143–148.
Anttila SA, Leinonen EV . A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7: 249–264.
Charney DS, Heninger GR, Sternberg DE, Redmond DE, Leckman JF, Maas JW et al. Presynaptic adrenergic receptor sensitivity in depression. The effect of long-term desipramine treatment. Arch Gen Psychiatry 1981; 38: 1334–1340.
Linner L, Arborelius L, Nomikos GG, Bertilsson L, Svensson TH . Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockade. Biol Psychiatry 1999; 46: 766–774.
Benkert O, Szegedi A, Kohnen R . Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61: 656–663.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Szegedi, A., Rujescu, D., Tadic, A. et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 5, 49–53 (2005). https://doi.org/10.1038/sj.tpj.6500289
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500289
Keywords
This article is cited by
-
Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT
BMC Psychiatry (2023)
-
The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder
BMC Psychiatry (2020)
-
Blood-based biomarkers predicting response to antidepressants
Journal of Neural Transmission (2019)
-
Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years
Drugs (2017)
-
Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies
CNS Drugs (2016)